Form 4: C4 Therapeutics Director Donna Grogan Acquires Shares in Lieu of Cash Compensation

Director Donna Grogan acquired 9,581 shares of C4 Therapeutics common stock in lieu of cash compensation, while disposing of 42,280 shares.

Summary

• On April 1, 2025, Donna Grogan, a director of C4 Therapeutics, acquired 9,581 shares of common stock.
• These shares were issued as compensation for her services as a non-employee director, in lieu of cash.
• The price of the stock at the time of the transaction was $1.435 per share, based on the closing market price on April 1, 2025.
• Grogan also disposed of 42,280 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a standard Form 4 filing detailing a director's stock transaction. The acquisition of shares in lieu of cash compensation is neither overtly positive nor negative, but the disposal of shares is a negative.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Negatives

• The disposal of 42,280 shares by the director could be seen as a negative sign.

Risks

• The market price of C4 Therapeutics' common stock could fluctuate, affecting the value of the acquired shares.
• Changes in the company's Non-Employee Director Compensation Policy could impact future compensation structures.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Directors often receive stock as part of their compensation, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages vary across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use a mix of cash and stock options to compensate their directors.
• The specific amount and structure depend on the company's size, performance, and compensation philosophy.
• Stock grants are a common way to align director interests with shareholder value.

Stakeholder Impact

• Shareholders may view the director's stock acquisition as a sign of confidence in the company.
• The transaction has a minimal direct impact on employees, customers, suppliers, and creditors.

Key Dates

Keywords

C4 Therapeutics, Director Compensation, Stock Acquisition, Form 4, Beneficial Ownership, Donna Grogan, CCCC